Arovella Therapeutics Limited
ASX: ALA.AX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael Baker
- Employees
- 27
- Headquarters
- Osborne Park, Australia
- IPO year
- 2002
- Market cap
- A$91.9M
- Website
- https://www.arovella.com
Loading ALA…
Loading profile data…Frequently asked questions about ALA
What does Arovella Therapeutics Limited (ALA.AX) do?
Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat short-term insomnia, which is marketed under the b...
Where does ALA.AX trade?
Arovella Therapeutics Limited (ALA.AX) trades on the Australian Securities Exchange.
What sector is ALA.AX in?
Arovella Therapeutics Limited (ALA.AX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Arovella Therapeutics Limited?
Michael Baker is the chief executive officer of Arovella Therapeutics Limited (ALA.AX).
Where is Arovella Therapeutics Limited headquartered?
Arovella Therapeutics Limited is headquartered in Australia.
Does ALA.AX pay a dividend?
Arovella Therapeutics Limited (ALA.AX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALA.AX go public?
Arovella Therapeutics Limited (ALA.AX) completed its initial public offering in 2002.